Merck CEO Rob Davis warns Congress and the Trump administration that restricting US-China biotech deals could lose the US its status as the world's biotech leader.
Merck CEO Rob Davis said he has warned Congress and the Trump administration that if they cut off or hamper US-China dealmaking, the US could …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui…
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic…
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
Chinese pharma companies are still striking global deals, but rising regulatory pressure is forcing buyers and sellers to rethink…
Bipartisan Michigan lawmakers unveil a bill subjecting US-China biotech deals to outbound investment screening, citing national…
